|IRB13-0585||A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and
Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors
|IRB13-0458||A Randomized, Phase III, Multicenter, Double Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination with 5-Fluorouracil, FOlinic Acid, and Oxaliplatin (mFOLFOX6) in Patients with Metastatic Her2-Negative, MET-Positive Gastroesophageal Cancer
|IRB13-0936||A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
|IRB13-0074||A Double-Blind, Placebo-Conotrolled, Randomized,Multicenter Phase III Study Evaluating the Efficacy and Safety of Pertuzumab in Combination with Trastuzumab
and Chemotherapy in Patients with HER2-Positive Metastatic Gastroesophageal Junction and Gastric Cancer
|IRB13-0757||A Prospective Observational Study to Examine, in Routine Clinical Practice in the US, Practice Patterns and Impact on Clinical Decision Making Associated with the FoundationOne┐ Next Generation Sequencing (NGS) Test
To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.